MARKET

ARVN

ARVN

ARVINAS HOLDING COMPANY, LLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.31
-0.50
-2.02%
After Hours: 24.31 0 0.00% 16:00 09/18 EDT
OPEN
24.77
PREV CLOSE
24.81
HIGH
25.82
LOW
23.68
VOLUME
291.41K
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
10.19
MARKET CAP
758.11M
P/E (TTM)
-4.3856
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARVN News

  • Benzinga's Top Upgrades, Downgrades For September 12, 2019
  • Benzinga.6d ago
  • New coverage - healthcare
  • Seeking Alpha - Article.6d ago
  • BMO Capital Initiates Coverage On Arvinas with Outperform Rating, Announces $34 Price Target
  • Benzinga.6d ago
  • Arvinas launches clinical development of ARV-471
  • Seeking Alpha - Article.08/27 11:17

More

Industry

Pharmaceuticals
+0.05%
Pharmaceuticals & Medical Research
-0.15%

Hot Stocks

Name
Price
%Change

About ARVN

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.
More

Webull offers Arvinas Inc (ARVN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.